Literature DB >> 25650113

Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma.

Yan Guo1,2, Qiao Pan3, Jing Zhang4, Xinyuan Xu1, Xiping Liu1, Qinhao Wang1, Ru Yi1, Xiaobo Xie5, Libo Yao2, Wenchao Liu2, Lan Shen1.   

Abstract

Transcriptional co-activator with PDZ-binding motif (TAZ) has been reported to be associated with carcinogenesis. However, the cellular function of TAZ in human hepatocellular carcinoma (HCC) remains elusive. In this study, an immunohistochemistry analysis revealed that the expression of TAZ in cancer tissue samples from 180 HCC patients was significantly higher than that in adjacent normal tissues. In addition, TAZ overexpression was significantly correlated with aggressive tumor characteristics such as tumor size, TNM stage, lymph node or distant metastasis, histological differentiation, and recurrent HCC (P < 0.05). The Kaplan-Meier test showed that TAZ-positive expression was related to a poor prognosis compared to TAZ-negative expression (P < 0.05). Furthermore, the expression level of TAZ was generally correlated with the invasiveness of cancer cells. The overexpression of TAZ in the Huh7 cell line, which endogenously expresses TAZ at low levels, significantly promoted cell proliferation, migration and invasion and inhibited apoptosis, whereas RNA interference-mediated knockdown of TAZ in the highly invasive cell line MHCC-97H significantly suppressed cell proliferation, migration and invasion in vitro and tumor formation in vivo.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25650113     DOI: 10.1002/jcb.25117

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  27 in total

Review 1.  A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression.

Authors:  Hong-Li Li; Qian-Yu Li; Min-Jie Jin; Chao-Fan Lu; Zhao-Yang Mu; Wei-Yi Xu; Jian Song; Yan Zhang; Sai-Yang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

2.  Automatic Multi-functional Integration Program (AMFIP) towards all-optical mechano-electrophysiology interrogation.

Authors:  Qin Luo; Justin Zhang; Miao Huang; Gaoming Lin; Mai Tanaka; Sharon Lepler; Juan Guan; Dietmar Siemann; Xin Tang
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

3.  YAP1 acts as a negative regulator of pro-tumor TAZ expression in esophageal squamous cell carcinoma.

Authors:  Yi-Zih Kuo; Ya-Rong Kang; Wei-Lun Chang; Lydia Chin-Ling Sim; Tzu-Chin Hsieh; Chu-Han Chang; Yi-Ching Wang; Ching-Jung Tsai; Li-Chun Huang; Sen-Tien Tsai; Li-Wha Wu
Journal:  Cell Oncol (Dordr)       Date:  2022-08-05       Impact factor: 7.051

4.  The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.

Authors:  Antonio Cigliano; Shanshan Zhang; Silvia Ribback; Sara Steinmann; Marcella Sini; Cindy E Ament; Kirsten Utpatel; Xinhua Song; Jingxiao Wang; Maria G Pilo; Fabian Berger; Haichuan Wang; Junyan Tao; Xiaolei Li; Giovanni M Pes; Serena Mancarella; Gianluigi Giannelli; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen; Katja Evert
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

5.  Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.

Authors:  Yun-Yong Park; Bo Hwa Sohn; Randy L Johnson; Myoung-Hee Kang; Sang Bae Kim; Jae-Jun Shim; Lingegowda S Mangala; Ji Hoon Kim; Jeong Eun Yoo; Cristian Rodriguez-Aguayo; Sunila Pradeep; Jun Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Woojin Jeong; Inn Sun Park; Young Nyun Park; Anil K Sood; Gordon B Mills; Ju-Seog Lee
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

6.  Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.

Authors:  Shanshan Zhang; Jingxiao Wang; Haichuan Wang; Lingling Fan; Biao Fan; Billy Zeng; Junyan Tao; Xiaolei Li; Li Che; Antonio Cigliano; Silvia Ribback; Frank Dombrowski; Bin Chen; Wenming Cong; Lixin Wei; Diego F Calvisi; Xin Chen
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

Review 7.  [Nonautonomous effects of oncogenic YAP in hepatocarcinogenesis].

Authors:  S Marquard; S Thomann; S M E Weiler; C Sticht; N Gretz; P Schirmacher; K Breuhahn
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 8.  Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.

Authors:  Iván M Moya; Georg Halder
Journal:  Nat Rev Mol Cell Biol       Date:  2019-04       Impact factor: 94.444

Review 9.  YAP/TAZ at the Roots of Cancer.

Authors:  Francesca Zanconato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

10.  The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.

Authors:  Hyunjin Park; Yangkyu Lee; Kiryang Lee; Hyejung Lee; Jeong Eun Yoo; Soomin Ahn; Young Nyun Park; Haeryoung Kim
Journal:  Pathol Oncol Res       Date:  2021-03-01       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.